Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
| Status: | Withdrawn |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 12/17/2016 |
| Start Date: | July 2014 |
| End Date: | December 2016 |
This clinical trial studies diffusion-weighted magnetic resonance imaging (MRI) in
identifying and localizing tumors in patients with non-small cell lung cancer undergoing
radiation therapy. Diagnostic procedures such as diffusion weighted MRI may help identify
where active cancer is to improve the targeting accuracy of radiotherapy. Comparing results
of diagnostic procedures done before, during, and after radiation therapy may help determine
how the location and volume of tumors changes over time and predict how the tumor will
respond to therapy.
identifying and localizing tumors in patients with non-small cell lung cancer undergoing
radiation therapy. Diagnostic procedures such as diffusion weighted MRI may help identify
where active cancer is to improve the targeting accuracy of radiotherapy. Comparing results
of diagnostic procedures done before, during, and after radiation therapy may help determine
how the location and volume of tumors changes over time and predict how the tumor will
respond to therapy.
PRIMARY OBJECTIVES:
I. Assess diffusion-weighted MRI as an early predictor for tumor response in patients with
non-small cell lung cancer (NSCLC).
II. Establish the potential of individualized radiotherapy targeting of radioresistant tumor
sub-volumes.
OUTLINE:
Patients undergo diffusion-weighted MRI within 4 weeks of radiation start (baseline), during
the second week of radiation therapy, during the fourth week of radiation therapy, and at 3
months after radiation therapy (post-treatment). Patients also undergo standard of care
4-dimensional (4D) computed tomography (CT) and fludeoxyglucose F 18 (FDG)-positron emission
tomography (PET) at the same time points.
I. Assess diffusion-weighted MRI as an early predictor for tumor response in patients with
non-small cell lung cancer (NSCLC).
II. Establish the potential of individualized radiotherapy targeting of radioresistant tumor
sub-volumes.
OUTLINE:
Patients undergo diffusion-weighted MRI within 4 weeks of radiation start (baseline), during
the second week of radiation therapy, during the fourth week of radiation therapy, and at 3
months after radiation therapy (post-treatment). Patients also undergo standard of care
4-dimensional (4D) computed tomography (CT) and fludeoxyglucose F 18 (FDG)-positron emission
tomography (PET) at the same time points.
Inclusion Criteria:
- Patients must be able to undergo MRI imaging; contrast application will be determined
according to institutional guidelines; patients with lung cancer or locally recurrent
lung cancer (following surgery) who are scheduled to receive external beam radiation
therapy for at least 6 weeks
- Tumor visible on planning CT scan
- Negative pregnancy test for women of childbearing potential prior to study entry
Exclusion Criteria:
- Patients requiring continuous supplemental oxygen
- Patients with metal implants including pace makers and defibrillators
- Patients with cerebral aneurysm clips or middle ear implant
- Patients with pain pump, a programmable shunt, or non-surgical metal (i.e. a foreign
body)
- Claustrophobic patients
- Prior radiotherapy to body area under investigation
- No vulnerable populations will be enrolled (prisoners, children, pregnant females, or
institutionalized individuals)
We found this trial at
1
site
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Elisabeth Weiss, MD
Phone: 804-628-2667
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
